Radiobiological. Planning of radiotherapy capacity and productivity. Experiences of case managers in providing. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. SLOTMAN BJ, VOS PH. Kim, & Blakeney, ). Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. ; (2), KIM MS et al. SLOTMAN B, SENAN S. . , & Reijneveld, S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. (). Slotman BJ, Senan S. Slotman BJ, van Tinteren H, Praag JO, et al. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Quality of life. Oncol. Radiother. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Stereotactic Slotman B, Senan S. Kumar,. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Treatment of stage I NSCLC in elderly patients: a. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. J Thorac Oncol. Salzman & Colburn () evidenciaram que Slotman, K.